Synchrony Financial has completed a full integration of its CareCredit patient‑financing solution with Fiserv’s Clover all‑in‑one commerce platform, enabling more than 40,000 health and wellness providers to accept CareCredit payments and submit new financing applications directly through Clover devices. The move eliminates the need for separate hardware or software, streamlining the checkout experience for both providers and patients.
The integration builds on a 2024 partnership that first allowed CareCredit payments to be processed through Clover. The new end‑to‑end workflow now covers the entire financing cycle—from application to approval—within the Clover ecosystem, making CareCredit the only patient‑financing solution available on the Clover App Market. This exclusivity positions Synchrony to capture a larger share of the growing elective‑care financing market, which is projected to expand as more providers seek flexible payment options for procedures that are not covered by traditional insurance.
By simplifying the financing process, Synchrony expects to deepen relationships with existing merchants and attract new ones, driving higher transaction volume and fee income. The expanded reach also improves patient access to CareCredit, potentially increasing the number of financed procedures and the average transaction size. Management views the integration as a key lever for scaling the Health & Wellness segment, which has shown resilient growth in recent quarters.
Executive Vice President and Chief Executive Officer of Health & Wellness, Beto Casellas, said the integration “provides a powerful operational advantage, enabling providers and small businesses to optimize their payment ecosystems, drive deeper customer loyalty, and significantly enhance enterprise growth.” Senior Vice President of SMB Sales and Partnerships at Fiserv, Katie Whalen, added that the partnership “helps healthcare practices operate more efficiently, streamline payment processes and enhance the patient experience.”
The announcement coincided with a broader market downturn and a proposal by then‑candidate Trump to cap credit‑card interest rates, which led to a 9% decline in Synchrony’s stock on the day of the announcement. The market reaction was driven by macro‑economic concerns rather than the integration itself, which analysts view as a positive strategic development for the company’s Health & Wellness platform.
Synchrony’s Q3 2025 results—revenue of $3.82 billion, up 2% YoY, and EPS of $2.86, beating estimates—illustrate the company’s ability to grow in a competitive environment. The new Clover integration is expected to build on that momentum by expanding the addressable market for CareCredit and reinforcing Synchrony’s position as a leading provider of patient financing solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.